ten23 well being, a worldwide contract growth and manufacturing group (CDMO), has expanded swissfillon’s manufacturing website in Visp, canton of Valais, Switzerland, which was acquired final October.
The FDA-inspected website in Visp at present provides sterile manufacturing of pre-filled syringes, vials, and cartridges for scientific trial and market provides. To allow additional development of its current manufacturing capability, ten23 well being is investing in an enlargement of supporting areas in an adjoining constructing.
This enlargement will present a further 1000 sq. meters of clean-room area for visible inspection and chilly storage and in addition embody clean-room area for extra companies, resembling supporting gadget meeting operations and labeling and secondary packaging. The dimension of the funding shouldn’t be disclosed.
Prof. Dr. Hanns-Christian Mahler, CEO of ten23 well being, commented, “Only five months ago, swissfillon joined ten23 health. This first expansion of the footprint in Visp is a strong commitment to our location in the Valais as well as Switzerland and a testimonial of the competent and experienced team at Visp. Furthermore, it is an important step in our long-term strategy to expand our manufacturing capacity for complex sterile dosage forms for our customers and their patients.”
swissfillon, a frontrunner within the sterile filling of advanced prescription drugs, was acquired by ten23 well being in October 2021. ten23 well being’s mixture of pharmaceutical growth companies with scientific and business fill & end companies provides purchasers an end-to-end set of capabilities.
ten23 well being launched its operations in Basel, Switzerland, in September 2021, with 4000 sq. meters of lab and workplace area, offering a piece atmosphere for as much as 150 colleagues. Benefiting from the gifted workforce within the Basel space, ten23 well being has constructed up a staff of completed leaders, scientists, and technicians over latest months.
